Securing the corporate development of a vaccine business

Situation

• Our client was active in developing prophylactic and therapeutic vaccines with proprietary adjuvant-free immunisation technology
• As an early stage company with significant cash needs, the company was looking to merge with a cash-generating entity to ensure long-term sustainability

Bionest Contribution

• Bionest was mandated by investors to validate the strategic rationale behind a specific transaction
   
• Bionest performed several strategic audits

1. Each company stand-alone and merged (synergies, etc.)

Key Results

• Bionest constructed and validated the new business case to investors

1. Newco able to generate cash-flows to develop internal pipeline of products
2. Newco positioned as a stronger candidate for a future fund-raising round